Please assess the completion status of the following clinical trial:

Trial Title: Prime Boost Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years and \< 65 years~* Common variable immunodeficiency according to the WHO criteria,~* Patients treated with intravenous or subcutaneous immunoglobulin.~* Written informed consent~* Absence of acute infections, or other evolutive diseases related to the (cancer, auto-immune disease...)~Exclusion Criteria:~* IgG subclass deficiency~* IgA selective deficiency,~* Other primary humoral deficiency (X-linked agammaglobulinemia, Hyper IgM syndrome),~* Long course treatment with corticosteroids \> 5mg per day~* Chemotherapy in the last 3 years,~* Prior pneumococcal vaccination in the last 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PPS (Type: ACTIVE_COMPARATOR): Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
- PnCJ PPS (Type: EXPERIMENTAL): Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).